<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815568</url>
  </required_header>
  <id_info>
    <org_study_id>2008-07-020</org_study_id>
    <nct_id>NCT00815568</nct_id>
  </id_info>
  <brief_title>Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)</brief_title>
  <official_title>Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the OS, RFS, and TRM after HCT with low-dose total
      body irradiation, fludarabine, and busulfan conditioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conventional allogeneic hematopoietic cell transplantation (HCT) for patients with
      hematological malignancies involves conditioning with high doses of systemic chemo/radiation
      therapy such as cyclophosphamide (CY) plus 1200 or 1000 cGy total body irradiation (TBI;
      CY/TBI) or busulfan (Bu) / CY (BuCy). Unfortunately, such regimens have been associated with
      significant toxicities, limiting their use to otherwise healthy, relatively young patients.

      Recently, Fludarabine plus 4 day dose of busulfan (FluBu4) containing myeloablative regimen
      has been introduced successfully without increasing transplant-related mortality (TRM). To
      improve transplant outcomes without increasing the risk of recurrence, Russell et al
      introduced 400cGy of TBI with antithymocyte (ATG, 4.5mg/Kg) into FluBu4 regimen with
      successful outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse of primary disease, overall survival, and occurrence of acute/chronic GVHD</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>AML</condition>
  <condition>MDS</condition>
  <condition>ALL</condition>
  <condition>CML</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate, busulfan</intervention_name>
    <description>Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)</description>
    <arm_group_label>Regimen</arm_group_label>
    <other_name>Fludarabine (FludaraÂ®, Berlex Laboratories, Richmond, CA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 15 years old and not more than 65 years old.

          -  ECOG performance status 0-2.

          -  Patients with AML or MDS with intermediate/unfavorable cytogenetics.

          -  Patients with ALL and CML ineligible for Cy/TBI conditioning.

          -  Patients with NHL or HD eligible to myeloablative HCT.

          -  Patients receiving unrelated BMT for AML, MDS, ALL, CML, NHL or HD.

          -  Consent form signed and dated prior to study specific procedures.

          -  Subject able to comply with the scheduled follow-up and with the management of
             toxicities.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Hwan Kim</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Hwan Kim</last_name>
    <phone>+82-2-3410-1768</phone>
    <email>drkiim@medimail.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dong Hwan Kim</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <last_update_submitted>December 29, 2008</last_update_submitted>
  <last_update_submitted_qc>December 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dong Hwan Kim</name_title>
    <organization>Dept of Hematology/Medical Oncology, Samsung Medical Center</organization>
  </responsible_party>
  <keyword>fludarabine</keyword>
  <keyword>busulfan</keyword>
  <keyword>total body irradiation</keyword>
  <keyword>conditioning regimen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

